bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1-10 from Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
Authors: Kozyreva Varvara K. , Kiseleva Anna A. , Ice Ryan J. , Jones Brandon C. , Loskutov Yuriy V. , Matalkah Fatimah , Smolkin Matthew B. , Marinak Kristina , Livengood Ryan H. , Salkeni Mohamad A. , Wen Sijin , Hazard Hannah W. , Layne Ginger P. , Walsh Callee M. , Cantrell Pamela S. , Kilby Greg W. , Mahavadi Sricharan , Shah Neal , Pugacheva Elena N.
Published: April 2023

File contains Supplementary figures: Figure 1: AUKRA analysis in TNBC cell lines in response to drug treatments. Additional TNBC migration/invasion analysis. Figure 2. Representative FACS analysis flow charts of TNBCs undergoing apoptosis. Figure 3. F-IHC analysis of tumors and lung metastases at the end point of treatment with vehicle, MLN8237, eribulin with indicated phospho-specific antibodies. Figure 4. Representative images of F-IHC, DNA (DAPI) staining of pulmonary tissue (metastases defined by the white outline) and mammary tumors. Figure 5. Fluorescent IHC analysis of metastases using pan-cytokeratin antibodies (Dako, green) to detect human tumor cells in lungs (mouse), DNA-DAPI. Figure 6. WB analysis of LC3BI/II, pAKT, AKT, alpha-tubulin expression in tumor cells isolated mammary tumors and lungs. Figure 7. F-IHC analysis of mammary tumor and lung metastases cells with p62, pAKT antibodies in the presence of Chloroquine. Figure 8. F-IHC staining of pulmonary tissue from, -cleaved Caspase-3, -phosphoAKT1/2. Figure 9. Cell growth analysis of Tumor cells PEN65 derived from PDX treated with indicated drugs. Figure 10. LAESI-MS MS/MS fragmentation of MLN8237 in dosed animal tumor tissue.
Movie S2: Cell body tracking of BT-549 treated with MLN8237 and/or eribulin during collagen invasion from Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
Authors: Kozyreva Varvara K. , Kiseleva Anna A. , Ice Ryan J. , Jones Brandon C. , Loskutov Yuriy V. , Matalkah Fatimah , Smolkin Matthew B. , Marinak Kristina , Livengood Ryan H. , Salkeni Mohamad A. , Wen Sijin , Hazard Hannah W. , Layne Ginger P. , Walsh Callee M. , Cantrell Pamela S. , Kilby Greg W. , Mahavadi Sricharan , Shah Neal , Pugacheva Elena N.
Published: April 2023

Representative movie of individual BT-549 cells treated with Vehicle, MLN8237, eribulin, or MLN8237/eribulin combination, suspended in collagen, and manually tracked over the course of 23 hours toward the serum chemoattractant-containing reservoir (left side of frame).
Supplementary Figure S2 from Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity
Authors: Kamel Walied A. , Sugihara Eiji , Nobusue Hiroyuki , Yamaguchi-Iwai Sayaka , Onishi Nobuyuki , Maki Kenta , Fukuchi Yumi , Matsuo Koichi , Muto Akihiro , Saya Hideyuki , Shimizu Takatsune
Published: April 2023

(A) Immunoblot analysis of AMPK and AKT in AXT cells treated with simvastatin for 12 h. The phosphorylation level of AMPK at Ser485 was not affected by simvastatin, while treatment of 1 μg/ml of insulin for 1 h (Ins) slightly enhanced phosphorylation level of AMPK at Ser485/Ser491. (B) Phase-contrast microscopy of AXT cells exposed to the indicated reagents for 20 h. (C, D) Immunoblot analysis of caspase-3 cleavage and either AMPK (B) or p38 MAPK (C) phosphorylation in AXT cells exposed to the indicated concentrations of 5-iodotubercidin or BIRB796, respectively, in the additional presence of 5 μM simvastatin for 20 h. (E) Immunoblot analysis of AMPK, p38 MAPK, and ACC phosphorylation in AXT cells treated with AICAR for 22 h. (F) Viability of AXT cells exposed to compound C in the additional presence of AICAR for 2 days. (G) Phase-contrast microscopy of AXT cells exposed to C3 transferase for 12 h.
Supplementary Figure S1 from Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity
Authors: Kamel Walied A. , Sugihara Eiji , Nobusue Hiroyuki , Yamaguchi-Iwai Sayaka , Onishi Nobuyuki , Maki Kenta , Fukuchi Yumi , Matsuo Koichi , Muto Akihiro , Saya Hideyuki , Shimizu Takatsune
Published: April 2023

(A) Phase-contrast microscopy of AXT cells treated with 10 μM simvastatin for 24 h in the absence or presence of mevalonate, GGPP, or FPP. (B) Representative migratory AXT cells stained with crystal violet after exposure to simvastatin for 12 h. (C, D) Flow cytometric analysis of DNA content in AXT cells treated with 5 μM simvastatin for 24 h in the absence or presence of mevalonate, GGPP, or FPP (C). The size of the sub-G1 fraction of cells was also determined (D).
Supplementary Document from Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity
Authors: Kamel Walied A. , Sugihara Eiji , Nobusue Hiroyuki , Yamaguchi-Iwai Sayaka , Onishi Nobuyuki , Maki Kenta , Fukuchi Yumi , Matsuo Koichi , Muto Akihiro , Saya Hideyuki , Shimizu Takatsune
Published: April 2023

Supplementary Figure Legends.
Supplementary Figure S1. from ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma
Authors: Futami Takashi , Okada Hidetsugu , Kihara Rumi , Kawase Tatsuya , Nakayama Ayako , Suzuki Tomoyuki , Kameda Minoru , Shindoh Nobuaki , Terasaka Tadashi , Hirano Masaaki , Kuromitsu Sadao
Published: April 2023

ASP5878 inhibited activation of FGFR signals in MDA-MB-453 xenograft model
Supplementary Data from ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma
Authors: Futami Takashi , Okada Hidetsugu , Kihara Rumi , Kawase Tatsuya , Nakayama Ayako , Suzuki Tomoyuki , Kameda Minoru , Shindoh Nobuaki , Terasaka Tadashi , Hirano Masaaki , Kuromitsu Sadao
Published: April 2023

Supplementary Figure legend. Supplementary Table S1. Kinase inhibitory profile of ASP5878
Supplementary Figure S1. Densitometric analysis of total Î²-catenin, active Î²-catenin, AurKA, p-AktSer473, p-GSK3Î²Ser9 and p-Mcl-1Ser159 expression. from Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation
Authors: Flores M. Luz , Castilla Carolina , Gasca Jessica , Medina Rafael , Pérez-Valderrama Begoña , Romero Francisco , Japón Miguel A. , Sáez Carmen
Published: April 2023

PKCÎ'-silenced PC3 (a) and LNCaP (b) cells were treated with DMSO or paclitaxel 2.5 ÂµM 48 hours. Histograms show densitometric and statistical analysis of indicated proteins from panels (c) and (d) of the Figure 3. Data are presented as mean{plus minus}S.E.M. *p<0.05, **p<0.01 and ***p<0.001 from Student's t-test (n{greater than or equal to}3).
Supplementary Table S2 from Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
Authors: Marlowe Timothy A. , Lenzo Felicia L. , Figel Sheila A. , Grapes Abigail T. , Cance William G.
Published: April 2023

RTK Array Data Excel File
Supplementary Materials and Supplementary Figures S1-S15 from Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
Authors: Marlowe Timothy A. , Lenzo Felicia L. , Figel Sheila A. , Grapes Abigail T. , Cance William G.
Published: April 2023

PathScan® RTK Signaling Antibody Array Kit Target Map (Cell Signaling) Antibodies and Other Reagents Fig. S1. Quantification of MDA-MB-453 and SkBr3 immunoblot experiments from Fig. 1; Fig. S2. Quantification of H292 and A549 immunoblot experiments from Fig. 1; Fig. S3. Defactinib-induced rapid compensatory RTK reprogramming in HER2-positive cells is dose-dependent and correlates with loss of FAK phosphorylation; Fig. S4. Defactinib-induced rapid compensatory RTK reprogramming in EGFR-positive cells occurs at low doses; Fig. S5. Total FAK levels regulate downstream activation of AKT/ERK pathways in HER2 positive cells; Fig. S6. FAK knockdown by siRNA in SkBr3 cells reduces FAK kinase inhibitor-induced RTK reprogramming; Fig. S7. Quantification of immunoblot experiments from Fig. 2; Fig. S8. Src is not required for FAK transphosphorylation downstream of HER2; Fig. S9. Coomassie-staining confirmation of protein loading in GST pull-down assays; Fig. S10. X-ray crystal structure of the FAK FERM domain and proximity of the Y397 linker region (AA 394-403) to the FERM F1 lobe; Fig. S11. EGFR-FAK HADDOCK docking studies; Fig. S12. Quantification of immunoblot experiments from Fig. 5; Fig. S13. RTK arrays of RTKHigh cell lines treated with defactinib; Fig. S14. RTK arrays of RTKLow cell lines treated with defactinib; Fig. S15. Overview of the FAK-kinase inhibitor drug resistance pathway through transphosphorylation of Y397 by HER2.
Table S2. Validation of cell line identification. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

Short Tandem Repeat profiling was performed on the Control and DasRes BCPAP, SW1736, C643, and Cal62 cell lines.
Supplementary tables from Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Authors: Boukalova Stepana , Stursa Jan , Werner Lukas , Ezrova Zuzana , Cerny Jiri , Bezawork-Geleta Ayenachew , Pecinova Alena , Dong Lanfeng , Drahota Zdenek , Neuzil Jiri
Published: April 2023

Supplementary tables 1 and 2
Figure S7. Prolonged inhibition of both Src and the MAP Kinase pathway results in a reduction in colony and tumor formation. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

A.) Clonogenic growth was detected by crystal violet staining in the BCPAP and Cal62 cell lines following 6 days of treatment with indicated inhibitors and 6 days of treatment release. B.) Colony area signal intensity was measured using Odyssey CLx imager (Li-Cor), and presented as percent fold change relative to the DMSO treated wells. Data as means +/- SEM (n=3; student t-test; *, P < 0.05, **, P < 0.005). C.) C. Comparison of the Cal62 Parental tumor volumes after 42 days of treatment with vehicle, 12.5mg/kg dasatinib BD, 0.5mg/kg trametinib QD, or the combination. Data as means +/- SEM (n=8; student t-test; **, P < 0.005)
Figure S6. Synergistic inhibition of thyroid cancer cell growth to dasatinib when combined with MEK 1/2 Inhibition. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

A.) Cell lines C643, Cal62, BCPAP, and SW1736, were treated with increasing doses of dasatinib ranging from (0.019 μM to 1.25 μM) for 72 hours, in combination with increasing doses of selumetinib (0.025 μM to 1 μM). Cell growth was measured using the Sulforhodamine B assay. Synergy was measured by determining the combination index using the Calcusyn software. Combinations that elicited a synergistic response are depicted by their corresponding shade of grey. (0.3-0.7,Synergism; 0.1-0.3, Strong Synergism; <0.1, Very Strong Synergism). B.) Cell lines BCPAP and Cal62 were treated with increasing doses of dasatinib ranging from (0.019 μM to 1.25 μM) for 72 hours, in combination with increasing doses of the ERK1/2 inhibitor SCH772984 (0.005 μM to 0.5 μM). Cell growth was measured using the Sulforhodamine B assay. Synergy was measured by determining the combination index using the Calcusyn software. Combinations that elicited a synergistic response are depicted by their corresponding shade of grey. (0.3-0.7, Synergism; 0.1-0.3, Strong Synergism; <0.1, Very Strong Synergism).
Legends to supplementary tables from Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Authors: Boukalova Stepana , Stursa Jan , Werner Lukas , Ezrova Zuzana , Cerny Jiri , Bezawork-Geleta Ayenachew , Pecinova Alena , Dong Lanfeng , Drahota Zdenek , Neuzil Jiri
Published: April 2023

This file contains legends to supplementary tables
Figure S3. Increased co-immunoprecipitation of B-Raf and c-Raf upon 5μM treatment with dasatinib in thyroid cancer cell lines. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

A.) Immunoprecipitation of c-Raf and western blot for B-Raf and c-Raf in whole cell lysates (WCL) following a three hour treatment with 5 μM dasatinib or an equivalent amount of DMSO, in the A375, BCPAP, and Cal62 cell lines. B.) Densitometry quantification of BRAF co-immunoprecipitations after c-Raf pulldown in the A375, BCPAP, and Cal62 cell lines following a three hour treatment with 5 μM dasatinib or an equivalent amount of DMSO. Quantification is based on at least 3 independent replicates for each cell line +/- SEM. C.) Immunoprecipitation for c-Raf and western blot for B-Raf and c-Raf and western blot for B-Raf and c-Raf in whole cell lysates (WCL) following a three hour treatment of with 0, .1, or 5 μM dasatinib or 5 μM saracatinib.
Supplementary Table S3C: Mutations/Sample from Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors
Authors: Hamm Christopher A. , Moran Diarmuid , Rao Kakuturu , Trusk Patricia B. , Pry Karen , Sausen Mark , Jones Siân , Velculescu Victor E. , Cristofanilli Massimo , Bacus Sarah
Published: April 2023

Mutation summary of individual tissue samples (Mutations with a frequency {greater than or equal to}1%)
Supplementary Table S3B: Copy Number change from Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors
Authors: Hamm Christopher A. , Moran Diarmuid , Rao Kakuturu , Trusk Patricia B. , Pry Karen , Sausen Mark , Jones Siân , Velculescu Victor E. , Cristofanilli Massimo , Bacus Sarah
Published: April 2023

Summary of copy number data.
Supplementary figures and Tables from Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET
Authors: Terwisscha van Scheltinga Anton G.T. , Ogasawara Annie , Pacheco Glenn , Vanderbilt Alexander N. , Tinianow Jeff N. , Gupta Nidhi , Li Dongwei , Firestein Ron , Marik Jan , Scales Suzie J. , Williams Simon-Peter
Published: April 2023

Supplementary Figure 1: Serum levels of AMA-MMAE in mice. Supplementary Figure 2: Correlation plot of tumor growth inhibition versus specific tumor uptake. Supplementary Table 1: Overview results. Supplementary Table 2: Tumor growth inhibition study of mice bearing OVCAR3-X2.1 cells comparing the efficacy of 5mg/kg and 20mg/kg doses
Supplemental Figure S3 from Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
Authors: Burke Patrick J. , Hamilton Joseph Z. , Jeffrey Scott C. , Hunter Joshua H. , Doronina Svetlana O. , Okeley Nicole M. , Miyamoto Jamie B. , Anderson Martha E. , Stone Ivan J. , Ulrich Michelle L. , Simmons Jessica K. , McKinney Erica E. , Senter Peter D. , Lyon Robert P.
Published: April 2023

In vitro dose response curves
Supplemental Methods, Figures, and Tables from Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia
Authors: Campbell Carly T. , Haladyna Jessica N. , Drubin David A. , Thomson Ty M. , Maria Michael J. , Yamauchi Taylor , Waters Nigel J. , Olhava Edward J. , Pollock Roy M. , Smith Jesse J. , Copeland Robert A. , Blakemore Stephen J. , Bernt Kathrin M. , Daigle Scott R.
Published: April 2023

Contains supplemental methods, figures, and tables 1, 2, 3, and 5
Supplementary Table S2 from Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
Authors: Emdal Kristina B. , Dittmann Antje , Reddy Raven J. , Lescarbeau Rebecca S. , Moores Sheri L. , Laquerre Sylvie , White Forest M.
Published: April 2023

Summary of data from target efficacy evaluation
Supplementary Table S1 from Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
Authors: Emdal Kristina B. , Dittmann Antje , Reddy Raven J. , Lescarbeau Rebecca S. , Moores Sheri L. , Laquerre Sylvie , White Forest M.
Published: April 2023

Summary of data from vehicle-treated tumors
Supplementary Figures and Legends from Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
Authors: Emdal Kristina B. , Dittmann Antje , Reddy Raven J. , Lescarbeau Rebecca S. , Moores Sheri L. , Laquerre Sylvie , White Forest M.
Published: April 2023

Supplementary Figures and Legends to accompany the text
Supplementary Figure S1 from PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
Authors: Packer Leisl M. , Geng Xinyan , Bonazzi Vanessa F. , Ju Robert J. , Mahon Clare E. , Cummings Margaret C. , Stephenson Sally-Anne , Pollock Pamela M.
Published: April 2023

Figure S1. AKT and ERK activity following increasing doses of BGJ398, GDC-0941, BYL719 and BKM120 in AN3CA and JHUEM2 cells.
MCT-16-0415R Supplementary Figure Legends from PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
Authors: Packer Leisl M. , Geng Xinyan , Bonazzi Vanessa F. , Ju Robert J. , Mahon Clare E. , Cummings Margaret C. , Stephenson Sally-Anne , Pollock Pamela M.
Published: April 2023

Supplementary Figure Legends 1-4.
Supplementary Figures and Tables from Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
Authors: Nelson-Taylor Sarah K. , Le Anh T. , Yoo Minjae , Schubert Laura , Mishall Katie M. , Doak Andrea , Varella-Garcia Marileila , Tan Aik-Choon , Doebele Robert C.
Published: April 2023

Supplementary Figures 1-8 Fig. S1: Cell viability of LC-2/ad, PR1, and PR2 cells treated with alectinib or cabozantinib. Fig. S2: RET break-apart FISH analysis of LC-2/ad, PR1, PR2, and H2228. Fig. S3: Phosphatase inhibitor treatment of PR1 and PR2 restores phospho-RET. Fig S4: NRAS Q61K increases NRAS GTP loading and induces RET inhibitor resistance in TPC1 cells. Fig S5: PR1 cells remain resistant to ponatinib after withdrawal from chronic ponatinib treatment. Fig S6: PR2 cells have lost RET signaling dependence. Fig S7: AXL signaling contributes to EGFR-mediated resistance to ROS1 inhibitors in HCC78-TAER cells. Fig S8: PR2 cells demonstrate plasticity when withdrawn from chronic ponatinib and display dual dependence on RET and EGFR. Supplementary Tables 1-3 Table S1: Normalized gene expression of RTKs in LC-2/ad, PR1 and PR2 cells. Table S2: Normalized gene expression of RTK ligands in LC-2/ad, PR1 and PR2 cells. Table S3: Normalized gene expression of protein tyrosine phosphatases in LC-2/ad, PR1, and PR2 cell lines.
Supplementary Data: Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (ulixertinib) from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Authors: Germann Ursula A. , Furey Brinley F. , Markland William , Hoover Russell R. , Aronov Alex M. , Roix Jeffrey J. , Hale Michael , Boucher Diane M. , Sorrell David A. , Martinez-Botella Gabriel , Fitzgibbon Matthew , Shapiro Paul , Wick Michael J. , Samadani Ramin , Meshaw Kathryn , Groover Anna , DeCrescenzo Gary , Namchuk Mark , Emery Caroline M. , Saha Saurabh , Welsch Dean J.
Published: April 2023

Supplementary materials and methods and supplementary figure legends
Figure S6 from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: Roth Gaël S. , Macek Jilkova Zuzana , Zeybek Kuyucu Ayca , Kurma Keerthi , Ahmad Pour Séyédéh Tayébéh , Abbadessa Giovanni , Yu Yi , Busser Benoit , Marche Patrice N. , Leroy Vincent , Decaens Thomas
Published: April 2023

Immunofluorescence staining of p-AKT on liver tissues
Figure S5 from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: Roth Gaël S. , Macek Jilkova Zuzana , Zeybek Kuyucu Ayca , Kurma Keerthi , Ahmad Pour Séyédéh Tayébéh , Abbadessa Giovanni , Yu Yi , Busser Benoit , Marche Patrice N. , Leroy Vincent , Decaens Thomas
Published: April 2023

AKT/pAKT expression in cell lines
Figure S3 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Authors: Germann Ursula A. , Furey Brinley F. , Markland William , Hoover Russell R. , Aronov Alex M. , Roix Jeffrey J. , Hale Michael , Boucher Diane M. , Sorrell David A. , Martinez-Botella Gabriel , Fitzgibbon Matthew , Shapiro Paul , Wick Michael J. , Samadani Ramin , Meshaw Kathryn , Groover Anna , DeCrescenzo Gary , Namchuk Mark , Emery Caroline M. , Saha Saurabh , Welsch Dean J.
Published: April 2023

(A) Percent change compared to DMSO treated control for following treatment with ERK inhibitors BVD-523 (BVD), Vx11 (Vx), GDC-0994 (GDC), and SCH772984 (SCH) are shown for pAkt (S473), pP70 S6K (S371 S394), pS6 Ribo Prot (S240 244) and pS6 Ribo Prot (S240 244), and (B) pBAD (S112), n=4 for each condition. (C) Western blot assays of cellular and nuclear fractions from RKO cell line following treatment with BVD-523, trametinib, SCH772984, or dabrafenib.
Figure S2 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Authors: Germann Ursula A. , Furey Brinley F. , Markland William , Hoover Russell R. , Aronov Alex M. , Roix Jeffrey J. , Hale Michael , Boucher Diane M. , Sorrell David A. , Martinez-Botella Gabriel , Fitzgibbon Matthew , Shapiro Paul , Wick Michael J. , Samadani Ramin , Meshaw Kathryn , Groover Anna , DeCrescenzo Gary , Namchuk Mark , Emery Caroline M. , Saha Saurabh , Welsch Dean J.
Published: April 2023

Using Reverse Phase Protein Array (RPPA), effects on proteins are measured in cell lines (A375, AN3Ca, Colo205, HCT116, HT29 and MIAPaCa2) following treatment with ERK1/2 inhibitors BVD-523 (BVD), Vx11e (Vx), GDC-0994 (GDC), or SCH772984 (SCH) (n=4 for each condition).
Supplementary Table S4 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Authors: Uitdehaag Joost C.M. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Willemsen-Seegers Nicole , de Vetter Judith R.F. , Dylus Jelle , van Doornmalen Antoon M. , Kooijman Jeffrey , Sawa Masaaki , van Gerwen Suzanne J.C. , de Man Jos , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

APC clustering, clustering with NCI60 data, extended version of Table 2
Supplementary figure legends from Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma
Authors: Ao Jian-Yang , Zhu Xiao-Dong , Chai Zong-Tao , Cai Hao , Zhang Yuan-Yuan , Zhang Ke-Zhi , Kong Ling-Qun , Zhang Ning , Ye Bo-Gen , Ma De-Ning , Sun Hui-Chuan
Published: April 2023

Supplementary figure legends
Supplemental Figure S6 from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Authors: Wu Shaofang , Wang Shuzhen , Zheng Siyuan , Verhaak Roel , Koul Dimpy , Yung W.K. Alfred
Published: April 2023

β-catenin depletion decreased cell resistance to PI3K/mTOR inhibition
Supplemental Tables from Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
Authors: Helsten Teresa , Kato Shumei , Schwaederle Maria , Tomson Brett N. , Buys Timon P.H. , Elkin Sheryl K. , Carter Jennifer L. , Kurzrock Razelle
Published: April 2023

Supplemental Table 1, Supplemental Table 2 (please see the separate spreadsheet), Supplemental Table 3
Supplemental Table 2 from Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
Authors: Helsten Teresa , Kato Shumei , Schwaederle Maria , Tomson Brett N. , Buys Timon P.H. , Elkin Sheryl K. , Carter Jennifer L. , Kurzrock Razelle
Published: April 2023

Spreadsheet for the individual cancer diagnosis and the cell cycle gene aberrations (N=1918)
Supplemental Figure S4 from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Authors: Wu Shaofang , Wang Shuzhen , Zheng Siyuan , Verhaak Roel , Koul Dimpy , Yung W.K. Alfred
Published: April 2023

Effect of MSK1 knock-down on cell growth.
Supplemental Methods from Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
Authors: Helsten Teresa , Kato Shumei , Schwaederle Maria , Tomson Brett N. , Buys Timon P.H. , Elkin Sheryl K. , Carter Jennifer L. , Kurzrock Razelle
Published: April 2023

Data from cBio Cancer Genomics Portal data (cBioPortal) was obtained from http://cbioportal.org to investigate cell cycle pathway genes (CCND1, CCND2, CCND3, CDK4/6, CDKN2A/B, CCNE 1 and RB1) and compared with current study (accessed on 3/16/2016).
Supplemental Figure S3 from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Authors: Wu Shaofang , Wang Shuzhen , Zheng Siyuan , Verhaak Roel , Koul Dimpy , Yung W.K. Alfred
Published: April 2023

ERK signaling pathway was activated by PI3K/mTOR inhibitor and mediated MSK1 phosphorylation
Supplemental Figures from Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
Authors: Helsten Teresa , Kato Shumei , Schwaederle Maria , Tomson Brett N. , Buys Timon P.H. , Elkin Sheryl K. , Carter Jennifer L. , Kurzrock Razelle
Published: April 2023

Supplemental Figure 1. A-H. and Supplemental Figure 2. A-H.
SUPPLEMENTAL FIGURE LEGEND from Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
Authors: Helsten Teresa , Kato Shumei , Schwaederle Maria , Tomson Brett N. , Buys Timon P.H. , Elkin Sheryl K. , Carter Jennifer L. , Kurzrock Razelle
Published: April 2023

Supplemental Figure Legend for Supplemental Figure 1. A-H. and Supplemental Figure 2. A-H.
Supplementary figure 6 from EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Authors: Civenni Gianluca , Longoni Nicole , Costales Paula , Dallavalle Cecilia , García Inclán Cristina , Albino Domenico , Nuñez Luz Elena , Morís Francisco , Carbone Giuseppina M. , Catapano Carlo V.
Published: April 2023

Supplementary figure 6. Ki-67 level assessed by immunofluorescence in tumor xenografts
Supplementary figure 5 from EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Authors: Civenni Gianluca , Longoni Nicole , Costales Paula , Dallavalle Cecilia , García Inclán Cristina , Albino Domenico , Nuñez Luz Elena , Morís Francisco , Carbone Giuseppina M. , Catapano Carlo V.
Published: April 2023

Supplementary figure 5.Cell cycle analysis by flow cytometry
Supplementary data from Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
Authors: Dillon Magnus T. , Barker Holly E. , Pedersen Malin , Hafsi Hind , Bhide Shreerang A. , Newbold Kate L. , Nutting Christopher M. , McLaughlin Martin , Harrington Kevin J.
Published: April 2023

Supplementary figures 1-4, supplementary table 1
Supplementary figure 1 from EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Authors: Civenni Gianluca , Longoni Nicole , Costales Paula , Dallavalle Cecilia , García Inclán Cristina , Albino Domenico , Nuñez Luz Elena , Morís Francisco , Carbone Giuseppina M. , Catapano Carlo V.
Published: April 2023

Supplementary figure 1. Immunofluorescence microscopy detection of p65
Supplementary Information from EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Authors: Civenni Gianluca , Longoni Nicole , Costales Paula , Dallavalle Cecilia , García Inclán Cristina , Albino Domenico , Nuñez Luz Elena , Morís Francisco , Carbone Giuseppina M. , Catapano Carlo V.
Published: April 2023

Supplementary methods and supplementary figure legends
Supplementary Table S1 and Supplementary Figures S1-S14 from Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR
Authors: Muralidharan Ranganayaki , Babu Anish , Amreddy Narsireddy , Srivastava Akhil , Chen Allshine , Zhao Yan Daniel , Kompella Uday B. , Munshi Anupama , Ramesh Rajagopal
Published: April 2023

Table S1. Table showing oligonucleotide primer sequence used in RT-PCR Figure S1. Physicochemical characterization of the nanoparticles shows shape, siRNA protection and siRNA release kinetics. Figure S2. Transferrin (Tf) ligand optimization on nanoparticles measured by fluorescence microscopy and fluorescence intensity. Figure S3.Nanoparticle specificity and receptor-mediated uptake studies. Figure S4. Western blotting showing HuRsiRNA4 but not other siRNAs used as controls reduced HuR protein expression. Figure S5. HuR mRNA expression analysis in nanoparticle-treated tumor and normal cells. Figure S6.Semi-quantitative analysis of HuR and HuR-regulated protein expression in A549 cells. Figure S7.Semi-quantitative analysis of HuR and HuR-regulated protein expression in HCC827 cells. Figure S8.Semi-quantitative analysis of HuR and HuR-regulated protein expression in MRC-9 cells. Figure S9. Western blot analysis shows HuR-TfNP treatments induces apoptosis in A549 cells. Figure S10. Molecular imaging showing biodistribution and kinetics of free ICG and ICG-TfNP in tumor-bearing and non-tumor-bearing naive mice respectively. Figure S11. Bioluminescence imaging showing tumor growth measurement over time in A549 tumor-bearing mice. Figure S12. Molecular analysis of HuR-TfNP-treated tumor tissues shows reduction in HuR mRNA and HuR-regulated proteins and induction of apoptosis. Figure S13. Immunohistochemical analysis of HuR-TfNP-treated A549 tumor tissues for changes in morphology, and in expression of HuR, CD31, KI67 and TUNEL positive cells. Figure S14.Immunohistochemical analysis of HuR-TfNP-treated HCC827 tumor tissues for changes in morphology, and in expression of HuR, CD31, and KI67.
Figure S6 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Authors: Shien Kazuhiko , Papadimitrakopoulou Vassiliki A. , Ruder Dennis , Behrens Carmen , Shen Li , Kalhor Neda , Song Juhee , Lee J. Jack , Wang Jing , Tang Ximing , Herbst Roy S. , Toyooka Shinichi , Girard Luc , Minna John D. , Kurie Jonathan M. , Wistuba Ignacio I. , Izzo Julie G.
Published: April 2023

Figure S6. Prevention of rhOSM-induced EMT-related changes by inhibition of OSMR/LIFR or STAT3. H23 cells were transfected with an siRNA specific for OSMR/LIFR, STAT3, JUN, or scrambled negative control for 72 hours. Cells were treated with rhOSM (1 ng/mL) for 1 week and cell lysates were analyzed for the indicated proteins by Western blotting.
Supplemental Figures 1-3 from PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species
Authors: Warfel Noel A. , Sainz Alva G. , Song Jin H. , Kraft Andrew S.
Published: April 2023

Supplemental Fig. 1. Hypoxia sensitizes breast and colon cancer cells to PIM inhibitors. Supplemental Fig. 2. PIM inhibitors kill hypoxic cancer cells in a HIF-1 independent manner. Supplemental Fig. 3. Chemical structure of pan-PIM kinase inhibitors.
Figure S4 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Authors: Shien Kazuhiko , Papadimitrakopoulou Vassiliki A. , Ruder Dennis , Behrens Carmen , Shen Li , Kalhor Neda , Song Juhee , Lee J. Jack , Wang Jing , Tang Ximing , Herbst Roy S. , Toyooka Shinichi , Girard Luc , Minna John D. , Kurie Jonathan M. , Wistuba Ignacio I. , Izzo Julie G.
Published: April 2023

Figure S4. rhOSM treatment resulted in EMT-associated changes in NSCLC cells. H23 cells treated or not treated (Mock) with rhOSM (10 ng/mL) for 1 week were subjected to phase-contrast imaging. rhOSM treatment caused morphological change to a spindle shape.
Supplementary Figure 1 from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals
Authors: Tao Le , Qiu Jianxin , Jiang Ming , Song Wenbin , Yeh Shuyuan , Yu Hong , Zang Lijuan , Xia Shujie , Chang Chawnshang
Published: April 2023

Pearson's correlation analysis of IL8, IL1 and HIF1A according to BLCA data set
Figure S2 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Authors: Shien Kazuhiko , Papadimitrakopoulou Vassiliki A. , Ruder Dennis , Behrens Carmen , Shen Li , Kalhor Neda , Song Juhee , Lee J. Jack , Wang Jing , Tang Ximing , Herbst Roy S. , Toyooka Shinichi , Girard Luc , Minna John D. , Kurie Jonathan M. , Wistuba Ignacio I. , Izzo Julie G.
Published: April 2023

Figure S2. Downstream pathway molecules activated by IL6 family proinflammatory cytokine stimulation in NSCLC cells. Five NSCLC cell lines were cultured with an IL6 family cytokine (rhIL6, rhOSM, rhLIF; 1 ng/mL) for the indicated time period under serum-starved conditions. Cell lysates were analyzed for the proteins shown by Western blotting.
Supplementary Figure Legends from Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer
Authors: Roh Yoon Jin , Kim Ju Hee , Kim In-Wook , Na Kun , Park Jae Myung , Choi Myung-Gyu
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 2 from Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer
Authors: Roh Yoon Jin , Kim Ju Hee , Kim In-Wook , Na Kun , Park Jae Myung , Choi Myung-Gyu
Published: April 2023

Characterization of the photosensitizers: A) The size distribution of PS-pNP was 40 nm and zeta-potential 35 mV. B) The fluorescence emission spectra of Ce6 and PS-pNP in DMSO (1ÂµM). C) 1H-NMR analysis of mPEG3-bPEI1-Ce61 (PS-pNP) in DMSO. D) The regression curve obtained by plotting the absorbance against the concentration of the standard Ce6 (663nm). Ce6 contents were calculated by comparing the absorption value to the standard (Â-†; the absorbance of PS-pNP, 1.2 mg/ml).
Supplemental Tables from Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
Authors: Jabbour-Leung Natalie A. , Chen Xian , Bui Tuyen , Jiang Yufeng , Yang Dong , Vijayaraghavan Smruthi , McArthur Mark J. , Hunt Kelly K. , Keyomarsi Khandan
Published: April 2023

Two supplemental Tables are included in this file. The title of the supplemental tables are: Supplemental Table 1A. Hormone receptor, Her2, p53 and Rb status of breast cell lines examined . Supplemental Table 1B. Cell number and drug concentrations used for concomitant and sequential combination drug treatment.
Supplemental Methods, Figure Legends and References from Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
Authors: Jabbour-Leung Natalie A. , Chen Xian , Bui Tuyen , Jiang Yufeng , Yang Dong , Vijayaraghavan Smruthi , McArthur Mark J. , Hunt Kelly K. , Keyomarsi Khandan
Published: April 2023

The attached file contains all the methods pertaining to supplemental figures and supplemental tables. Additionally, the Materials and Methods that were previously published by our lab and used in this ms with minor modifications, are included in the supplemental methods with proper citations provided. This file also includes all the figure legends pertaining to the 6 supplemental figures as well the references cited in the supplemental methods.
Table S1 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Authors: Alcaraz-Sanabria Ana , Nieto-Jiménez Cristina , Corrales-Sánchez Verónica , Serrano-Oviedo Leticia , Andrés-Pretel Fernando , Montero Juan Carlos , Burgos Miguel , Llopis Juan , Galán-Moya Eva María , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

List of identified deregulated genes between non-transformed human epithelial ovarian cells and ovarian carcinoma cells.
Legends to Supplementary Material from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Authors: Alcaraz-Sanabria Ana , Nieto-Jiménez Cristina , Corrales-Sánchez Verónica , Serrano-Oviedo Leticia , Andrés-Pretel Fernando , Montero Juan Carlos , Burgos Miguel , Llopis Juan , Galán-Moya Eva María , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Legends to Supplementary table and figures
Figure S6 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Authors: Alcaraz-Sanabria Ana , Nieto-Jiménez Cristina , Corrales-Sánchez Verónica , Serrano-Oviedo Leticia , Andrés-Pretel Fernando , Montero Juan Carlos , Burgos Miguel , Llopis Juan , Galán-Moya Eva María , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Effect of Alisertib, LY2603618 and chemotherapies alone or in combination, in OVCAR3 and OVCAR8 growth as tumorspheres.
Supplementary Table 2 from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
Authors: Dréan Amy , Williamson Chris T. , Brough Rachel , Brandsma Inger , Menon Malini , Konde Asha , Garcia-Murillas Isaac , Pemberton Helen N. , Frankum Jessica , Rafiq Rumana , Badham Nicholas , Campbell James , Gulati Aditi , Turner Nicholas C. , Pettitt Stephen J. , Ashworth Alan , Lord Christopher J.
Published: April 2023

ddPCR probe and primer design
Figure S5 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Authors: Alcaraz-Sanabria Ana , Nieto-Jiménez Cristina , Corrales-Sánchez Verónica , Serrano-Oviedo Leticia , Andrés-Pretel Fernando , Montero Juan Carlos , Burgos Miguel , Llopis Juan , Galán-Moya Eva María , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Flow cytometry data plots of CD44 and CD133.
Supplementary Table 1 from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
Authors: Dréan Amy , Williamson Chris T. , Brough Rachel , Brandsma Inger , Menon Malini , Konde Asha , Garcia-Murillas Isaac , Pemberton Helen N. , Frankum Jessica , Rafiq Rumana , Badham Nicholas , Campbell James , Gulati Aditi , Turner Nicholas C. , Pettitt Stephen J. , Ashworth Alan , Lord Christopher J.
Published: April 2023

Sequencing of additional CRISPR-induced PARPi resistant CAPAN1 clones
Supplementary Figures 1-10 from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
Authors: Dréan Amy , Williamson Chris T. , Brough Rachel , Brandsma Inger , Menon Malini , Konde Asha , Garcia-Murillas Isaac , Pemberton Helen N. , Frankum Jessica , Rafiq Rumana , Badham Nicholas , Campbell James , Gulati Aditi , Turner Nicholas C. , Pettitt Stephen J. , Ashworth Alan , Lord Christopher J.
Published: April 2023

Figure S1: Characterisation of CAPAN1-B2S* Figure S2: Characterisation of SUM149-B1S* Figure S3: Sensitivity of ddPCR assay. Figure S4: Olaparib and talazoparib select for secondary mutant tumour cells. Figure S5: DLD1 tumour cells have a fitness advantage over DLD1.BRCA2-/- cells in vitro. Figure S6: Olaparib has little efficacy in mixed CAPAN-1 xenografts. Figure S7: Exome sequencing of CAPAN-1.B2.S* shows retention of TP53 mutations. Figure S8: Exome sequencing of SUM149.B1.S* show retention of TP53 mutation. Figure S9: BRCA-proficient and -deficient cells exhibit sensitivity to additional DNA damaging agents. Figure S10: AZD-1775 causes an active S phase reduction in both CAPAN1 and CAPAN-1.B2.S* cells.
Figure S2 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Authors: Alcaraz-Sanabria Ana , Nieto-Jiménez Cristina , Corrales-Sánchez Verónica , Serrano-Oviedo Leticia , Andrés-Pretel Fernando , Montero Juan Carlos , Burgos Miguel , Llopis Juan , Galán-Moya Eva María , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Alisertib and LY2603618 impair formation of colonies and induce citotoxicity in ovarian cancer cells.
Supplementary. Fig. S6 from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

TALEN gene editing for eliminating expression of p44 in SK-OV-3 cells
Supplementary. Fig. S5 from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

Mass-Spec Analysis Results of Control Group
Supplementary. Fig. S4 from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

Mass-Spec Analysis Results of Treatment Group
Supplementary. Fig. S3 from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

NCBI BLAST Results of Mass-Spec Analysis
Figure S6 from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

Effects of CDK10 expression on cell cycle. Flow cytometry analysis of RKO/NeoB, RKO/CDK10 DN and RKO/CDK10 WT cell cycles. (A) One representative experiment is shown. (B) Quantitative analysis of the different cell phase populations. Results represent three independent experiments.
Supplementary. Fig. S2 from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

Triptolide reduced c-Myc and c-myc mRNA in MDR cells
Figure S4 from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

Effect of CDK10 expression on transcript levels of CDKs. CDK2, CDK4, CDK5, CDK6 and CDK9 expression in (A) MIP101 and (B) RKO CDK10 WT and DN overexpressing cells. Results represents n = 3, means {plus minus} SD.
Supplementary information from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

Descriptions of supplementary data
Figure S3 from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

Effect of CDK10 expression on cell proliferation and apoptosis in vivo. Immunostaining of CDK10 WT and DN overexpressing MIP101 xenografts for Ki-67 (upper panel, red) and cleaved caspase-3 (lower panel, red) and counterstained with Hoechst 33258 (blue).
Supplementary figures S1-S9 from Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression
Authors: Shi Liang , Lin Hui , Li Gonghui , Jin Ren-An , Xu Junjie , Sun Yin , Ma Wen-Lung , Yeh Shuyuan , Cai Xiujun , Chang Chawnshang
Published: April 2023

Supplemental Fig. S1 Endogenous AR expression in various HCC cell lines; Supplemental Fig. S2 Multiple E:T ratio for NK cells against HCC cells; Supplemental Fig. S3 Tunel assay for NK cells against SNU-423 cells; Supplemental Fig. S4 IL-12p35 release of HCC cells with various AR; Supplemental Fig. S5 MAGNET V2.0 calculated correlation between IL12A and AR; Supplemental Fig. S6 Distribution of NK cells in different region of HCC;Supplemental Fig. S7 IL-12p35 release induced by sorafenib treatment; Supplemental Fig. S8 Ectopic AR in HCC cells interrupted sorafenib induced IL-12A; Supplemental Fig. S9 Correlation analysis for animal tumor samples staining
Figure S1-3 from Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma
Authors: Zhou Feng , Shimoda Michiko , Olney Laura , Lyu Yuanzhi , Tran Khiem , Jiang Guochun , Nakano Kazushi , Davis Ryan R. , Tepper Clifford G. , Maverakis Emanual , Campbell Mel , Li Yuanpei , Dandekar Satya , Izumiya Yoshihiro
Published: April 2023

S-Figure 1. KSHV reactivation by PEP005; S-Figure 2. Chromatin immunoprecipitations; S-Figure 3. Intersection analysis of genes differentially-expressed in response to each treatment in different PEL cell lines.
Supplementary Figures Legends from Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma
Authors: Markowitz Daniel , Powell Caitlin , Tran Nhan L. , Berens Michael E. , Ryken Timothy C. , Vanan Magimairajan , Rosen Lisa , He Mingzhu , Sun Shan , Symons Marc , Al-Abed Yousef , Ruggieri Rosamaria
Published: April 2023

Legends to Supplementary Figures
Supplemental Figure 7 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Authors: Sinik Lenka , Minson Katherine A. , Tentler John J. , Carrico Jacqueline , Bagby Stacey M. , Robinson William A. , Kami Rotem , Burstyn-Cohen Tal , Eckhardt S. Gail , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Supplemental Figure 7 shows combined UNC2025 and vemurafenib treatment is tolerated in mice.